TNX-103 not checked

Tenax Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pulmonary Hypertension Associated With HFpEF (2 trials), Pulmonary Hypertension
Main trialPhase 3
“This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).”In the company’s words, NCT05983250 on ClinicalTrials.gov

Other drugs for Pulmonary Hypertension Associated With HFpEF

All 42 drugs for Pulmonary Hypertension Associated With HFpEF

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Jun 2026 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Phase 3Active, not recruiting 30 Jun 2028 LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Phase 3Enrolling by invitation Mar 2029 Long-Term Open-Label Extension Study of Oral Levosimendan
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow TNX-103

Following is part of Solo: you see every change to TNX-103 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in